BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22082529)

  • 1. Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells.
    Yoon YK; Kim HP; Song SH; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Cancer Lett; 2012 Mar; 316(1):77-84. PubMed ID: 22082529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
    Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
    Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
    BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.
    Endo H; Okami J; Okuyama H; Nishizawa Y; Imamura F; Inoue M
    Oncogene; 2017 May; 36(20):2824-2834. PubMed ID: 27893711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.
    Izumchenko E; Chang X; Michailidi C; Kagohara L; Ravi R; Paz K; Brait M; Hoque MO; Ling S; Bedi A; Sidransky D
    Cancer Res; 2014 Jul; 74(14):3995-4005. PubMed ID: 24830724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations.
    Walsh AM; Lazzara MJ
    Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
    Siu A; Virtanen C; Jongstra J
    Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells.
    Walsh AM; Lazzara MJ
    J Cell Sci; 2013 Oct; 126(Pt 19):4339-48. PubMed ID: 23868981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
    Yoon YK; Kim HP; Han SW; Hur HS; Oh DY; Im SA; Bang YJ; Kim TY
    Mol Cancer Ther; 2009 Sep; 8(9):2526-36. PubMed ID: 19755509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
    Vu HL; Rosenbaum S; Capparelli C; Purwin TJ; Davies MA; Berger AC; Aplin AE
    J Invest Dermatol; 2016 Feb; 136(2):453-463. PubMed ID: 26967478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
    Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
    Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation.
    van Houdt WJ; Hoogwater FJ; de Bruijn MT; Emmink BL; Nijkamp MW; Raats DA; van der Groep P; van Diest P; Borel Rinkes IH; Kranenburg O
    Neoplasia; 2010 Jun; 12(6):443-52. PubMed ID: 20563247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.